AV45 Amyloid PET Templates available

AV45 PET normalization templates have been derived from ADNI data. Users with ADNI access rights can download the templates for normal controls and subjects with Alzheimer's disease as illustrated in this screen capture. A description of the template methodology is available for direct download. Seamless integration into PMOD is planned for version 3.9.

Use of PMOD in Summer School on Neuroimaging

Michael Winterdahl from the University of Aarhus successfully used the PNEURO tool for the excercises in his Interdisciplinary Summer School on Neuroimaging.

OLINDA/EXM Dosimetry based on PMOD Residence Times

PMOD was applied by Hjornevik et al. for the calculation of the [18]F-FTC-146 residence times in humans.

Build 6 of version 3.8 is ready for download

Build 6 of version 3.8 is ready for download. See release notes for details.

PMOD Service Point at SNMMI in Denver

After the successful launch at last year's annual meeting in San Diego, PMOD will run for a second time a PMOD Service Point at SNMMI 2017 in Denver.

Build 11 of version 3.7 is ready for download

Build 11 of version 3.7 is ready for download. See release notes for details.

Use of PMOD for Preclinical PET Imaging Course in Tromsø

In November, the second Norwegian PhD course in preclinical PET imaging took place at the University of Tromsø. It included lectures, demonstrations as well as hands-on laboratory work covering many aspects of small animal imaging. An essential part of the two week course was the practical quantification of the acquired PET/CT and SPECT/CT images using PMOD, taking advantage of a course license provided by PMOD Technologies. Reportedly, course adviser Samuel Kuttner and his students were highly satisfied with the performance and versatility of the software.

PMOD Usage in Publications

The widespread use of PMOD in research has been documented in our publication list.
Comparison with Pubmed indicates that PMOD was applied in at least 5% of the PET-related publications in 2015.

New Product Release 3.8

Version 3.8 is ready for download. See release notes for details.

Build 13 of version 3.6 is ready for download

Build 13 of version 3.6 is ready for download. See release notes for details.

Prediction of MCI Outcome using 18F-FDG-PET and PALZ

Japanese researchers evaluated MCI to AD conversion based on FDG PET and MRI in a multicenter study. Multivariate logistic regression analysis identified the PALZ-derived PET score as the most significant predictive factor distinguishing AD converters from non-converters.

Automated Neuroanatomical Structures for Quantitative Amyloid PET

A recent study by Tuszynski et al. compares software tools, including PNEURO, for the automatic contouring of brain structures. It clearly documents value and reliability of PNEURO for the analysis of amyloid PET images, making it a viable alternative to the standard manual outlining.

New Product Release 3.7

Version 3.7 is ready for download. See release notes for details.

VOI Application Video

A new video illustrates the use of PMOD's volume-of-interest facilities for the outlining and analysis of a brain tumor.

Use of PMOD for PET and MRI Imaging in Neuroscience Course

The Neuroscience Center of Geneva organizes the Master in Neuroscience program and coordinates the Ph.D. program in the Lemanic region together with the University of Lausanne and the EPFL. An important part of the PET and MRI Imaging in Neuroscience course is the practical quantification of human PET images using PMOD. "PMOD covers all data processing steps with an intuitive user interface. We consider PMOD as a reference for quantification of PET and SPECT tracers." (Dr. Philippe Millet)

Regional Statistics Video

A new video illustrates the use of the PMOD R console for analyzing the regional outcomes of a study.

Use of PNEURO for Analyzing Large ADNI Data Set

In a recent study Brendel et al. studied the effects of reference region selection and partial-volume correction with amyloid PET. They fully automatically processed the data of 962 subjects using PNEURO. Their conclusion is that detection of longitudinal amyloid increase is optimized when using partial-volume correction and white matter as reference tissue.

Pipeline Processing Video

A new video illustrates how to apply pipeline processing in PMOD.

Fuse It Overview Video

A new video gives an impression of the Fuse It tool introduced with Pmod 3.6.

First PMOD Services Project Completed

PMOD Services offers a range of support options for study protocol design, instrumentation setup, image analysis methodology, and result statistics. Since its inception this summer, customers already took advantage of dedicated support. In one successfully completed project, tailored kinetic model variants were developed to study a PET tracer with real data and simulations. In another ongoing project, preclinical baseline and follow-up SPECT data were outsourced to PMOD Services for the analysis and comparison of tracer uptake in various organs.

New Product Release 3.6

Version 3.6 is ready for download. See release notes for details.

Build 10 of version 3.5 is ready for download.

Build 10 of version 3.5 is ready for download. See release notes for details.

New Course: Statistics with PMOD

A new PMOD statistics training course was successfully organized in collaboration with Prof. K. Herholz. Besides covering basic statistics in PMOD via the R interface, it focused on the newly developed population statistics which handles the issue of multiple comparisons properly.

New Product Release 3.5

Version 3.5 is ready for download. See release notes for details.

Collaboration in European FP7 Project MultISyn

The MultISyn project aims at developing a biomarker for the α-Synuclein aggregation based on a multimodality workflow. PMOD is in charge of developing the image analysis software, including PET and fMRI quantification as well as multi-parametric data mining.

Introducing PSEG, a Tool for Preclinical Image Segmentation

The new PSEG tool addresses the needs for computer-aided image segmentation in preclinical research. By applying patented clustering technology, PSEG offers a fast and reliable solution for outlining organs and lesions in dynamic rodent PET studies.

Video Resources

A suite of product videos have been uploaded to aid interested scientists understanding the scope of the individual PMOD modules. Each 5-minute clip presents the backround of a module and showcases its flavour by an actual demo.

Collaboration with CEA, France, on Segmentation of preclinical PET Images

The CEA with its site Service Hospitalier Frederic Joliot in Orsay, France, and PMOD have signed a second collaboration agreement. It grants PMOD a license for patented segmentation methodology which will be leveraged to develop an automated organ and lesion segmentation module for dynamic preclinical animal PET studies.

New PNEURO Training Course

A new PNEURO course has been developed in collaboration with Prof. A. Hammers, a renowned expert in the field of atlas-based brain image analysis. It covers applied neuroanatomy, the principles of atlas-based brain region definition, and trains in the actual analysis of PET data with different uptake characteristics.

New Product Release 3.4, introducing PNEURO and PCARDM

Version 3.4 is ready for download. See release notes for details.
Selection of the major highlights:
  • New tool PNEURO making it easy to generate objective and accurate brain area outlines by streamlined workflows.
  • New tool PCARDM for the qualitative and quantitative analysis of cardiac perfusion MR images.
  • Direct interface to the R open-source statistics environment.
  • Spectral analysis added to the kinetic modeling tool PKIN.

License Agreement with Imperial Innovations, London

Imperial Innovations, London, and PMOD Technologies have signed a license agreement for the N30R83 maximum probability atlas developed by Prof. A. Hammers. PMOD plans to incorporate this methodology for the objective and automatic delineation of human brain regions applicable to PET, SPECT and MR images in the upcoming PNEURO tool.

New Product Release 3.3

Version 3.3 is ready for download. See release notes for details.
Selection of the major highlights:
  • Reorganization of the fusion tool interface, particularly of the initialization part of matching.
  • Support for plasma fraction functions in the kinetic modeling tool, as well as area-under-the-curve (AUC) calculations. Dedicated model configurations can be saved with user-defined names.
  • Extension of VOI features: automatic brain VOI generation, region-growing methods in 2D and 3D, VOI intersection calculation, VOI erosion and dilation, contour interpolation.
  • PMOD real-time aquisition tool (PSAMPLE) for devices such as the twilite swisstrace blood sampler.

5th Annual Renewal of Maintenance Agreement with Genentech, Inc.

Two groups at Genentech, Inc., a member of the Roche Group, are longstanding users of PMOD. The company has renewed their "Maintenance Agreement for PMOD Software" for a fifth consecutive annual period.

Twilite Blood Sampling Device (Swisstrace)

The gold standard of PET quantification is kinetic modeling using information about the tracer concentration in arterial blood. To promote wider use of PET quantification Swisstrace has introduced a new online blood sampling device for humans and animals. It is highly sensitive and accurate due to coincidence counting with LYSO crystals, and the unique design makes it fully MR compatible.

PMOD is proud to provide the PSAMPLE data acquisition software for this sophisticated instrument.

Collaboration with CEA, France, on Parcellation of MR/PET Images

The CEA with its site Service Hospitalier Frederic Joliot in Orsay, France, and PMOD have have signed a collaboration agreement. It grants PMOD a license for patented brain parcellation methodology, together with a knowledge base of segmented MR images. The objective of the collaboration is to provide a highly accurate basal ganglia segmentation and cortex parcellation tool on the basis of human T1-MR images.

New Criterion to Predict Progression from MCI to AD

A new study by Herholz et al (J Nucl Med August 1, 2011 vol. 52, 1218-1226) introduces a new "PET Score" criterion derived from FDG brain PET scans. It is shown to be a valid imaging biomarker for monitoring the progression of mild cognitive impairment (MCI) to Alzheimer's disease (AD). Its superior test-retest reliability and signal strength will allow the reduction in the number of subjects needed in clinical trials or shortening of study duration substantially.

The PET score can be easily calculated from the analysis of FDG brain images with PMOD's current Alzheimer's tool (PALZ). The next version to the tool available in Oct. 2011 will yield the "PET Score" as an additional result.

New Product Release 3.2

Version 3.2 is ready for download. See release notes for details.
Selection of the major highlights:
  • Complete work-flow oriented revision of the PXMOD tool. Additionally, the image fusion tool is directly integrated into PXMOD to support the pixel-oriented comparison of parametric maps.
  • Support for various automated partial-volume correction (PVC) methods. The VOI-based approach implements Rousset's GTM method. The VOIs can be manually outlined or automatically derived from standard VOI templates. A brain MRI based approach implements the method proposed by Muller-Gartner. It includes the required PET-MR matching as well as the MRI segmentation without the need for any user interaction.
  • Ability to calculate and apply the inverse of all transforms (rigid and elastic) calculated in the fusion tool. Furthermore, VOIs can now also be transformed, not only images. Together, these new features allow easily transferring template VOIs to the patient images for performing the template-based statistics on the original PET images.
  • A new version (ATL) was developed which supports all the features required for CFR part 11 compliant data analyses. It is mainly intended for CROs and includes full audit trails, data protection and advanced reporting.

Maintenance Agreement with RIKEN, Kobe, Japan

The RIKEN institution located in Kobe, Japan, comprises a prominent Molecular Imaging Research Program. RIKEN's imaging group and PMOD have signed a maintenance agreement to further strengthen their longstanding collaboration.

Performance Assessment of PALZ Tool

Haense et al. have tested the performance of the PALZ tool with data from two different databases. The study confirms the high accuracy of FDG PET with PALZ for the discrimination between Alzheimer's Dementia patients and normal controls. Furthermore it demonstrates that PALZ can be equally applied to studies with eyes open or closed during the uptake phase. Only 7 out of 464 images had to be excluded from the analysis due to a failure of the normalization procedure.

New Product Release 3.1

The new 3.1 product version is now available. It incorporates more than 130 improvements with main highlights in VOI and kinetic modeling functionalities, as documented in the Release Notes.
Selection of some notable improvements:
  • Flexible inclusion/exclusion functionality on the contour and VOI level to create complex VOIs from which inner parts are spared.
  • Usage of indvidual pixels to form VOIs or to extend existing VOIs; exclusion of pixels from existing VOIs.
  • Combination of masks with VOIs, for example to restrict contour VOIs to gray matter segments.
  • Introduction of geometric VOI objects which can be scaled and moved in all directions.
  • Randomized fitting of kinetic models with randomly generated initial parameters for avoiding local minima.
  • Automatic initial parameter determination for compartment models by the linear least squares method.
  • User-defined parameter defaults per kinetic model.
  • Extended history of the tested kinetic models which allows to easily compare their outcome.
  • Improved user interface for more easily producing nice Volume Renderings in the 3D tool.
CAUTION: As a consequence of the improvements, kinetic modeling in the 3.1 version may return slightly different results than the prior versions. Please refer to the Release Notes for details.

All users with purchased base version 3.0 are encouraged to freely download and use this significantly improved PMOD version. During the installation you will be able to import the configuration of your prior installation. In this way your working environment will be easily migrated. Note that your old license file will work with version 3.1.

All other users need to purchase an upgrade for using the 3.1 version.

Note: Builds of the current PMOD version are prepared at irregular intervals, mainly for fixing bugs. We strongly recommend using the latest build of a version.

DopaSoft: Clinical Software Development for IBA Molecular

PMOD has developed a diagnostic software package called DopaSoft for the analysis of FDOPA PET scans. This package will be rolled out in the Bordeaux area by IBA in the first quarter of 2010.

Site License for Karolinska Institute, Sweden

The research group at the Karolinska Institutet PET Centre is a large-scale user of PMOD's kinetic modeling and image fusion solutions. In order to consolidate and further advance the usage of the PMOD software, a site license agreement has been signed.

Opinion of Prof. Christer Halldin and Dr. Andrea Varrone: "PMOD is a very useful and versatile tool for image and data analysis in PET research, providing a variety of solutions for optimal quantification of neuroreceptor PET studies."

Product Release 3.0

The new 3.0 product version is now available. It includes numerous improvements and new features, as documented in the release notes. Some of the notable changes are
  • VOI: Undo function for contour VOIs.
  • VOI: Outlining supported in all plane directions (alos in coronal and sagittal).
  • VOI: Revised user interface which offers more image space.
  • PKIN: Metabolite correction models are included.
  • Database/DICOM Server: are now included in the base license.
  • PXMOD: New models and masking functionality added.
  • PFUS: Taskbar with hotkeys for frequent tasks added.
All users with purchased base version 2.9 or 2.95 are encouraged to freely download and use this improved release.
Note that your old license file will work.

Clinical Evaluation of the Alzheimer's Discrimination Tool

The IRCCS Centro San Giovanni di Dio of Brescia is the Italian national centre for research and care of Alzheimer's and mental diseases. The IRCSS will assess the value of the PALZ tool in the workout of preclinical Alzheimer's disease.

New Office located in Zurich

PMOD Technologies has opened a new office in the center of Zurich, Switzerland.

Reselling Agreement for Taiwan and China

PMOD Technologies has signed an agreement with Cold Spring Biotech Corp, Taipei. As of Nov. 5, 2007, Cold Spring Biotech Corp has the exclusive rights for distributing the PMOD software in Taiwan and China.

Reselling Agreement for Japan

PMOD Technologies has signed an agreement with PET Technology Supplies, Tokyo, Japan. As of July 1, 2007, PET Technology Supplies has the exclusive rights for distributing the PMOD software in Japan.

OEM Agreement with Gamma Medica-Ideas

PMOD Technologies has signed an agreement with Gamma Medica-Ideas, Northridge, CA, U.S.A. Gamma Medica-Ideas will offer PMOD as an option with their suite of animal scanners for advanced post processing.

OEM Agreement with GEM-Imaging

PMOD Technologies has signed an agreement with General Equipment for Medical Imaging, Paterna (Valencia), Spain. GEM-Imaging will offer PMOD as an option with their new animal PET scanner for advanced post processing.

OEM Agreement with MILabs

PMOD Technologies has signed an agreement with Molecular Imaging Laboratories, Utrecht, The Netherlands. MILabs will offer PMOD as an option with their new, high-resolution animal U-SPECT scanner for advanced post processing.

Collaboration with University of Ottawa Heart Institute

PMOD Technologies and Dr. deKemp from the Ottawa Heart Institute have started a collaboration to improve the cardiac quantification within PMOD. The main focus is on streamlining the application for routine usage with Ammonia and Rubidium, and on extending the range of validated models further.

Reselling Agreement for Korea

PMOD Technologies has signed an agreement with New Korea Industrial Co., Ltd, Seoul, Korea. As of Dec. 1, 2004, New Korea has the exclusive rights for distributing the PMOD software in Korea.

Agreement with Max-Planck-Institute Cologne

The Max-Planck-Institute (MPI) Cologne and PMOD Technologies have signed a research contract on May 18, 2004. PMOD Technologies is entitled to transform the automatic Alzheimer discrimination methodology developed by Dr. Herholz from MPI into a new analysis tool. Dr. Herholz’ methodology is based on the data of 110 normal FDG scans and has been tested with the data of 395 patients, as documented in NeuroImage 17, 302-316 (2002). The new PMOD tool will make an automated evaluation available to the public which has the potential for widespread clinical use to support diagnosis of dementia at a very early stage.

Transferal of Rights to PMOD Technologies Ltd

The exclusive rights for the PMOD software are transfered from the University of Zurich to PMOD Technologies.

Establishment of PMOD Technologies Ltd

PMOD Technologies is established as a spin-off company of the University of Zurich, Switzerland.